Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$62.31 USD

62.31
1,176,615

+0.38 (0.61%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $62.33 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?

Style Box ETF report for IWM

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Halozyme Therapeutics (HALO) Down 34.4% Since Last Earnings Report: Can It Rebound?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Strength Seen in Halozyme Therapeutics (HALO): Can Its 5.3% Jump Turn into More Strength?

Halozyme Therapeutics (HALO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options

Investors need to pay close attention to Halozyme Therapeutics (HALO) stock based on the movements in the options market lately.

Should Vanguard Russell 2000 ETF (VTWO) Be on Your Investing Radar?

Style Box ETF report for VTWO

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

Style Box ETF report for IWO

Should Vanguard Russell 2000 Growth ETF (VTWG) Be on Your Investing Radar?

Style Box ETF report for VTWG

Halozyme (HALO) Q4 Earnings Top, Revenues Miss, Stock Down

Halozyme Therapeutics (HALO) reports mixed fourth-quarter results. Stock is down in the after-market hours in response to the earnings results.

Halozyme Therapeutics (HALO) Q4 Earnings Surpass Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 2.13% and 2.46%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock?

Investors need to pay close attention to Halozyme (HALO) stock based on the movements in the options market lately.

Should iShares Russell 2000 ETF (IWM) Be on Your Investing Radar?

Style Box ETF report for IWM

Andrew Rocco headshot

Market on Tipping Point of New Bull Trend: These 5 Charts Illustrate Why

You never really know when a new bull trend has arrived for sure. However, by looking at different sides of the market you can begin to put the pieces of the puzzle together.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

Smart Beta ETF report for XBI

Halozyme (HALO) Down 9.2% on Weak 2023 Financial Guidance

Though Halozyme (HALO) expects a year-over-year increase in revenues and earnings for 2023, the company's guidance fell short of Wall Street expectations.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Sector ETF report for XBI

Should iShares Russell 2000 Growth ETF (IWO) Be on Your Investing Radar?

Style Box ETF report for IWO

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks.com featured highlights Halozyme Therapeutics, Arista Networks and Citizens Financial Group

Halozyme Therapeutics, Arista Networks and Citizens Financial Group have been highlighted in this Screen of The Week article.

Tirthankar Chakraborty headshot

3 Stocks to Keep an Eye on for Earnings Growth in 2023

As 2023 approaches, its prudent to have a look at stocks like Halozyme Therapeutics (HALO), Arista Networks (ANET) & Citizens Financial Group (CFG) for solid earnings growth.

Halozyme Therapeutics (HALO) Up 16.2% Since Last Earnings Report: Can It Continue?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Halozyme (HALO) Stock Rises 35% in the Year so Far: Here's Why

Halozyme (HALO) is gaining on its proprietary drug delivery technology, ENHANZE. It expects strong revenues on the back of robust demand for its new partnered drugs.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.